Daratumumab and its potential in the treatment of multiple myeloma: Overview of the preclinical and clinical development

Therapeutic Advances in Hematology

Volumn 6, Issue 3, 2015, Pages 120-127

  Phipps, Colin ^a   Chen, Yunxin ^a   Gopalakrishnan, Sathish ^a   Tan, Daryl ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b RAFFLES HOSPITAL   (Singapore)

Author keywords

daratumumab; monoclonal; myeloma

Indexed keywords

EID: 84993709930     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620715572295     Document Type: Review

References (35)

1. Arrigo A. Tanaka K. Goldberg A. Welch W. (1988) Identity of the 19s ‘prosome’ particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 331: 192–194.
2. Avet-Loiseau H. Attal M. Campion L. Caillot D. Hulin C. Marit G. et al. (2012) Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30: 1949–1952.
3. Chillemi A. Zaccarello G. Quarona V. Ferracin M. Ghimenti C. Massaia M. et al. (2013) Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 19: 99–108.
4. de Weers M. Tai Y. van der Veer M. Bakker J. Vink T. Jacobs D. et al. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186: 1840–1848.
5. Dhodapkar M. Kelly T. Theus A. Athota A. Barlogie B. Sanderson R. (1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99: 368–371.
6. Ellis J. Barber K. Tutt A. Hale C. Lewis A. Glennie M. et al. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol 155: 925–937.
7. Gangatharan S. Carney D. Prince H. Wolf M. Januszewicz E. Ritchie D. et al. (2012) Emergence of central nervous system myeloma in the era of novel agents. Hematol Oncol 30: 170–174.
8. Janssen Research & Development, LLC (2015 a) A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=758644&version=HealthProfessional
9. Janssen Research & Development, LLC (2015 b) A study of JNJ-54767414 (humax CD38) (anti-CD38 monoclonal antibody) in combination with backbone treatments for the treatment of patients with multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01998971.
10. Kong S. Li X. Nahar S. Song W. de Weers M. Parren P. et al. (2011) Daratumumab directly induces human multiple myeloma cell death and acts synergistically with conventional and novel anti-myeloma drugs. In: American Society of Hematology Annual Meeting, 5 December, United States.
11. Kumar S. Rajkumar S. Dispenzieri A. Lacy M. Hayman S. Buadi F. et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516–2520.
12. Lee H. (2006) Structure and enzymatic functions of human CD38. Mol Med 12: 317–323.
13. Lokhorst H. Laubach J. Nahi H. Plesner T. Gimsing P. Hansson M. et al. (2014) Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). In: American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2014. J Clin Oncol 32: 5s (suppl; abstr 8513)
14. Lokhorst H. Plesner T. Gimsing P. Nahi H. Minnema M. Lassen U. et al. (2013) Phase I / II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. In: American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2013. J Clin Oncol 31 (suppl; abstr 8512).
15. Malavasi F. Deaglio S. Damle R. Cutrona G. Ferrarini M. Chiorazzi N. (2011) CD38 and chronic lymphocytic leukemia: a decade later. Blood 118: 3470–3478.
16. Malavasi F. Deaglio S. Funaro A. Ferrero E. Horenstein A. Ortolan E. et al. (2008) Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 88: 841–886.
17. Marco Jansen J. Boross P. Overdijk M. van Bueren J. Parren P. Leusen J. (2012) Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via fc receptor-mediated crosslinking. In: American Society of Haematology Annual Meeting, 9 December, Atlanta, GA.
18. Mateos M. Oriol A. Martinez-Lopez J. Gutierrez N. Teruel A. de Paz R. et al. (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934–941.
19. Moreau P. Mateos M. Bladé J. Benboubker L. de La Rubia J. Facon T. et al. (2014) An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. In: 56th ASH Annual Meeting and Exposition, 6 December, San Francisco, CA.
20. Nair B. van Rhee F. Shaughnessy J. Jr Anaissie E. Szymonifka J. Hoering A. et al. (2010) Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD Maintenance. Blood 115: 4168–4173.
21. Nijhof I. van Bueren J. van Kessel B. de Weers M. Bakker J. Parren P. et al. (2012) Towards CD38-targeted immunochemotherapy of multiple myeloma: significant improvement of anti-myeloma effects of lenalidomide, bortezomib and dexamethason by CD38-specific antibody daratumumab, even in chemotherapy resistant / intolerant patients. In: American Society of Hematology Annual Meeting, Atlanta, GA. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4988.
22. Ocio E. Richardson P. Rajkumar S. Palumbo A. Mateos M. Orlowski R. et al. (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (IMWG). Leukemia 28: 525–542.
23. Overdijk M. Verploegen V. Marijn B. van Egmond M. Groen R. Martens A. et al. (2012) Phagocytosis is a mechanism of action for daratumumab. In: American Society of Hematology Annual Meeting, 10 December, Atlanta, GA.
24. Plesner T. Arkenau H. Lokhorst H. Gimsing P. Krejcik J. Lemech C. et al. (2014) Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. In: American Society of Clinical Oncology Annual Meeting, 7 December, Chicago, IL.
25. Plesner T. Lokhorst H. Gimsing P. Nahi H. Lisby S. Richardson P. (2012) Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I / II study. In: American Society Hematology Annual Meeting, 9 December, United States.
26. Short K. Rajkumar S. Larson D. Buadi F. Hayman S. Dispenzieri A. et al. (2011) Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 25: 906–908.
27. Siegel R. Naishadham D. Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
28. Tai Y. Podar K. Gupta D. Lin B. Young G. Akiyama M. et al. (2002) CD40 activation induces P53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 99: 1419–1427.
29. Tai Y. Soydan E. Song W. Fulciniti M. Kim K. Hong F. et al. (2009) CS 1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via C-maf-mediated interactions with bone marrow stromal cells. Blood 113: 4309–4318.
30. Urashima M. Chauhan D. Hatziyanni M. Ogata A. Hollenbaugh D. Aruffo A. et al. (1996) CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk Res 20: 507–515.
31. US National Library of Medicine (2014 a) A study of combination of daratumumanb and velcade (Bortezomib) melphalan-prednisone (DVMP) compared to velcade melphalan-prednisone (VMP) in participants with previously untreated multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02195479
32. US National Library of Medicine (2014 b) Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02136134
33. van der Veer M. de Weers M. van Kessel B. Bakker J. Wittebol S. Parren P. et al. (2011 a) The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 1: e41.
34. van der Veer M. de Weers M. van Kessel B. Bakker J. Wittebol S. Parren P. et al. (2011 b) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96: 284–290.
35. Wijdenes J. Vooijs W. Clement C. Post J. Morard F. Vita N. et al. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94: 318–323.